Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Five things for pharma marketers to know: Thursday, February 9, 2017
Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Five things for pharma marketers to know: Tuesday, January 31, 2017
The FDA approves new indication for Jardiance; Novartis’ CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy
Five things for pharma marketers to know: Thursday, November 17, 2016
Sprout investors sue Valeant; FDA raises safety concerns for Cempra’s experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients